Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

22.99
-0.3500-1.50%
Post-market: 22.990.00000.00%19:30 EDT
Volume:815.51K
Turnover:18.85M
Market Cap:2.38B
PE:-6.74
High:23.75
Open:23.72
Low:22.85
Close:23.34
52wk High:28.23
52wk Low:8.99
Shares:103.41M
Float Shares:74.11M
Volume Ratio:0.44
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:5.90
PE(LYR):-7.53

Loading ...

Nurix Therapeutics Q2 Operating Expenses USD 103.247 Million

THOMSON REUTERS
·
Jul 10

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jul 10

Analysts Conflicted on These Healthcare Names: Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 08

U.S. Earnings Preview: After Market Close July 7

Dow Jones
·
Jul 08

Top News Today: Tech Shares Power U.S. Stocks Higher

Dow Jones
·
Jul 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 06

Nurix Chief Legal Officer Christine Ring Disposes of USD 259,399.29 in Common Shares

Reuters
·
Jul 03

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

TIPRANKS
·
Jul 01

Nurix Therapeutics assumed with an Outperform at Oppenheimer

TIPRANKS
·
Jun 29

Nurix Therapeutics (NRIX) Is Up 30.5% After Landmark Roche BTK Degrader Collaboration - What's Changed

Simply Wall St.
·
Jun 29

Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 28,935 Common Shares for $580,006

Reuters
·
Jun 26

Nurix Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis

Reuters
·
Jun 18

Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Nurix Therapeutics Price Target Maintained With a $34.00/Share by Needham

Dow Jones
·
Jun 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 12

Nurix reports 22.1-month median PFS in Phase 1a trial of BTK degrader bexobrutideg for relapsed/refractory CLL/SLL

Reuters
·
Jun 11

Nurix Therapeutics - Reports 92.9% Objective Response Rate in Second Line Btki-Exposed, Bcl2i-NaÏVe Cll Patients

THOMSON REUTERS
·
Jun 11